Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole

被引：0
|
作者：
Sabnis, Gauri J. [1 ]
Jelovac, Danijela [1 ]
Long, Brian J. [1 ]
Schayowitz, Adam [1 ]
Belosay, Aashvini [1 ]
Brodie, Angela M. H. [1 ]
机构：
[1] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2316
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells
    Schmitz, Frank
    Heit, Antje
    Dreher, Stefan
    Eisenaecher, Katharina
    Mages, Joerg
    Haas, Tobias
    Krug, Anne
    Janssen, Klaus-Peter
    Kirschning, Carsten J.
    Wagner, Hermann
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (11) : 2981 - 2992
  • [42] Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells
    Wagner, H.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 298 : 106 - 106
  • [43] Folate Deficiency Inhibits Mammalian Target of Rapamycin (mTOR) Signaling in Cultured Primary Human Trophoblast Cells
    Rosario, Fredrick J.
    Powell, Theresa L.
    Jansson, Thomas
    REPRODUCTIVE SCIENCES, 2012, 19 (S3) : 380A - 380A
  • [44] PATHOLOGICAL FINDINGS OF A SUBEPENDYMAL GIANT CELL ASTROCYTOMA FOLLOWING TREATMENT WITH MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITOR RAPAMYCIN
    Cheng, Sylvia
    Bartels, Ute
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S81 - S81
  • [45] Does inhibition of aromatase by the specific inhibitor letrozole radiosensitize human breast cancer cells in vitro?
    Schmid-Bielenberg, D.
    Ohneseit, P. A.
    Krebiehl, G.
    Rodemann, H. P.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 79 - 79
  • [46] Renal outcomes in lung transplant recipients treated with the mammalian target of rapamycin (mTOR) inhibitor everolimus
    Coughlan, Timothy
    Ivulich, Steve
    Slack, Ryan
    Choi, Boyoun
    Paul, Eldho
    Snell, Greg
    Menahem, Solomon
    TRANSPLANTATION, 2016, 100 (07) : S109 - S109
  • [47] Risk of rash and stomatitis with temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor: A meta-analysis.
    Gomez Fernandez, C.
    Balagula, Y.
    Wu, S.
    Su, X.
    Feldman, D. R.
    Rathkopf, D. E.
    Lacouture, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer
    Albert, Jeffrey M.
    Kim, Kwang Woon
    Cao, Carolyn
    Lu, Bo
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1183 - 1189
  • [49] Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer
    Ciruelos, Eva
    Cortes-Funes, Hernan
    Ghanem, Ismael
    Manso, Luis
    Arteaga, Carlos
    ANTI-CANCER DRUGS, 2013, 24 (08) : 769 - 780
  • [50] mTOR kinase inhibitor AZD8055 reverses acquired rapamycin resistance in prostate cancer cells
    Dai, Yao
    Siemann, Dietmar
    CANCER RESEARCH, 2022, 82 (12)
12345